Commentary

Dr. Barbieri's Response


 

Dr. Barbieri responds: Until more data come in, avoid magnesium sulfate

I appreciate the perspectives provided by Dr. Toofanian and Dr. Klobutcher, as well as by Dr. Daniels and colleagues. As experienced clinicians, they all clearly recognize how difficult and frustrating it is to treat the multifactorial causes of prematurity, including the contribution of complex environmental factors such as psychosocial stress in the mother.

I agree with Dr. Toofanian that multimodal treatment of preterm labor might delay birth, but that great care must be taken to avoid adverse effects, such as maternal pulmonary edema.

Dr. Daniels and associates are correct that we need additional studies comparing magnesium sulfate to a placebo for the treatment of preterm labor. Until additional data indicate the effectiveness of magnesium, it is my “subjective” opinion that patients in preterm labor are best served by treatment with nifedipine, a β-agonist, or indomethacin. A continuing concern is that magnesium sulfate treatment of preterm labor, especially at dosages greater than 2 g/h, may be associated with adverse newborn outcomes.

Recommended Reading

Early Fetal Growth Rate Helps Predict Macrosomia
MDedge ObGyn
Outcomes Improved With Low Threshold for GDM Diagnosis
MDedge ObGyn
Data Watch: Gestational Diabetes Follows Its Own Road
MDedge ObGyn
Alpha Fetoprotein Adjustment in Diabetes May Be Insufficient
MDedge ObGyn
Oral Drugs Show Promise in Gestational Diabetes
MDedge ObGyn
Podocyturia May Signal Preeclampsia Risk Early
MDedge ObGyn
Delivery Urged at 36 Weeks With Placenta Previa
MDedge ObGyn
Classical Incision Advised In Some Circumstances
MDedge ObGyn
Aspiration Benign, Helpful For Investigating Breast Mass
MDedge ObGyn
MRgFUS Could Be New Wave in Breast Ca Ablation
MDedge ObGyn